BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 26616436)

  • 1. Stimulation of neuronal cells by culture supernatant of T lymphocytes triggered by anti-CD3 mAb followed by propagation in the presence of interleukin-2.
    Ishiguro M; Okada A; Asai K; Kojima K; Okada H
    Microbiol Immunol; 2016 Jan; 60(1):47-55. PubMed ID: 26616436
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced human lymphokine-activated killer cell function after brief exposure to granulocyte-macrophage-colony stimulating factor.
    Baxevanis CN; Dedoussis GV; Papadopoulos NG; Missitzis I; Beroukas C; Stathopoulos GP; Papamichail M
    Cancer; 1995 Oct; 76(7):1253-60. PubMed ID: 8630906
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of granulocyte-macrophage colony-stimulating factor on lymphokine-activated killer cell induction.
    Stewart-Akers AM; Cairns JS; Tweardy DJ; McCarthy SA
    Blood; 1993 May; 81(10):2671-8. PubMed ID: 8490177
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lymphokine-activated killer (LAK) cell generation from peripheral blood stem cells by in vitro incubation with low-dose interleukin-2 plus granulocyte-macrophage colony-stimulating factor.
    Herrera C; García-Pérez MJ; Ramirez R; Martín C; Alvarez MA; Martinez F; Gómez P; García-Castellano JM; Torres A
    Bone Marrow Transplant; 1997 Mar; 19(6):545-51. PubMed ID: 9085733
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Granulocyte/macrophage-colony-stimulating factor augments lymphokine-activated killer activity from lymphocytes via macrophages in lung cancer patients.
    Takahashi K; Saito S; Kamamura Y; Katakawa M; Monden Y
    Cancer Immunol Immunother; 2000 Dec; 49(10):537-43. PubMed ID: 11129324
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Granulocyte-monocyte colony-stimulating-factor augments the interleukin-2-induced cytotoxic activity of human lymphocytes in the absence and presence of mouse or chimeric monoclonal antibodies (mAb 17-1A).
    Masucci G; Ragnhammar P; Wersäll P; Mellstedt H
    Cancer Immunol Immunother; 1990; 31(4):231-5. PubMed ID: 2199042
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interleukin-2 modulates the expression of lymphocyte function-associated antigen-one (LFA-1) and p150,95 during the generation of lymphokine-activated killer (LAK) cells.
    Grant AJ; Merchant RE; Hall RE
    Immunology; 1989 Jan; 66(1):117-24. PubMed ID: 15493273
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lymphokine-activated killer cell regulation of T-cell-mediated immunity to Candida albicans.
    Wei S; Blanchard DK; McMillen S; Djeu JY
    Infect Immun; 1992 Sep; 60(9):3586-95. PubMed ID: 1500166
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Granulocyte-macrophage colony-stimulating factor augments lymphokine-activated killer activity from pleural cavity mononuclear cells of lung cancer patients without malignant effusion.
    Takahashi K; Sone S; Saito S; Kamamura Y; Uyama T; Ogura T; Monden Y
    Jpn J Cancer Res; 1995 Sep; 86(9):861-6. PubMed ID: 7591964
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of recombinant human granulocyte-macrophage colony-stimulating factor on the induction of lymphokine-activated killer cells in vitro.
    Okamura S; Tanaka T; Yamaga S; Omori F; Niho Y
    Int J Immunopharmacol; 1991; 13(5):587-93. PubMed ID: 1783473
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Up-regulation by granulocyte-macrophage colony-stimulating factor (GM-CSF) of induction of lymphokine (IL-2)-activated killer (LAK) cells by human blood monocytes.
    Singh SM; Sone S; Inamura N; Ogura T
    Int J Cancer; 1989 Jul; 44(1):170-6. PubMed ID: 2663733
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Coinduction of granulocyte-macrophage colony-stimulating factor release and lymphokine-activated killer cell susceptibility in monocytes by interleukin-2 via interleukin-2 receptor beta.
    Epling-Burnette PK; Wei S; Blanchard DK; Spranzi E; Djeu JY
    Blood; 1993 Jun; 81(11):3130-7. PubMed ID: 8499646
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Suppression of human monocyte function against Candida albicans by autologous IL-2-induced lymphokine-activated killer cells.
    Wei S; Serbousek D; McMillen S; Blanchard DK; Djeu JY
    J Immunol; 1991 Jan; 146(1):337-42. PubMed ID: 1898605
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GM-CSF-mediated proliferation induction improves the susceptibility of leukemia cells to lymphokine-activated killer cells.
    Teichmann JV; Ludwig WD; Thiel E
    Int J Hematol; 1992 Jun; 55(3):255-64. PubMed ID: 1498316
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Injury to autologous normal tissues and tumors mediated by lymphokine-activated killer (LAK) cells generated in vitro from peripheral blood mononuclear cells of glioblastoma patients.
    Fujimiya Y; Suzuki Y; Katakura R; Ohno T
    J Hematother; 1999 Feb; 8(1):29-37. PubMed ID: 10192299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Postoperative immunosuppression cascade and immunotherapy using lymphokine-activated killer cells for patients with esophageal cancer: possible application for compensatory anti-inflammatory response syndrome.
    Yamaguchi Y; Hihara J; Hironaka K; Ohshita A; Okita R; Okawaki M; Matsuura K; Nagamine I; Ikeda T; Ohara M; Hamai Y
    Oncol Rep; 2006 Apr; 15(4):895-901. PubMed ID: 16525677
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Production of granulocyte/macrophage-colony-stimulating factor by human natural killer cells. Modulation by the p75 subunit of the interleukin 2 receptor and by the CD2 receptor.
    Levitt LJ; Nagler A; Lee F; Abrams J; Shatsky M; Thompson D
    J Clin Invest; 1991 Jul; 88(1):67-75. PubMed ID: 1676038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lymphokine-activated killer (LAK) cells. V. 8-Mercaptoguanosine as an IL-2-sparing agent in LAK generation.
    Thompson RA; Ballas ZK
    J Immunol; 1990 Nov; 145(10):3524-31. PubMed ID: 1700014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of human leukocyte antigen-mismatched allogeneic lymphokine-activated killer cells and interleukin-2 in the adoptive immunotherapy of patients with malignancies.
    Kimoto Y
    Hum Cell; 1992 Sep; 5(3):226-35. PubMed ID: 1467321
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of eosinophils in interleukin-2/lymphokine-activated killer cell therapy.
    Ishimitsu T; Torisu M
    Surgery; 1993 Feb; 113(2):192-9. PubMed ID: 8381564
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.